5.58
Schlusskurs vom Vortag:
$6.14
Offen:
$5.89
24-Stunden-Volumen:
1.97M
Relative Volume:
2.03
Marktkapitalisierung:
$446.76M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-119.87M
KGV:
-3.0829
EPS:
-1.81
Netto-Cashflow:
$-109.90M
1W Leistung:
-24.29%
1M Leistung:
-30.51%
6M Leistung:
-45.56%
1J Leistung:
-59.42%
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Firmenname
Oric Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 388-5600
Adresse
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Vergleichen Sie ORIC mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ORIC
Oric Pharmaceuticals Inc
|
5.58 | 446.76M | 0 | -119.87M | -109.90M | -1.81 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-10-31 | Eingeleitet | Wells Fargo | Overweight |
2024-09-06 | Eingeleitet | Stifel | Buy |
2024-02-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
2023-09-22 | Eingeleitet | Wedbush | Outperform |
2023-03-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2023-03-21 | Hochstufung | Guggenheim | Neutral → Buy |
2023-03-16 | Hochstufung | Oppenheimer | Perform → Outperform |
2022-07-18 | Fortgesetzt | Oppenheimer | Perform |
2022-04-04 | Hochstufung | Citigroup | Neutral → Buy |
2022-03-25 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2022-03-22 | Herabstufung | Citigroup | Buy → Neutral |
2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
2022-03-22 | Herabstufung | Oppenheimer | Outperform → Perform |
2021-07-06 | Hochstufung | Citigroup | Neutral → Buy |
2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
2020-08-13 | Eingeleitet | Robert W. Baird | Outperform |
2020-08-06 | Hochstufung | Citigroup | Neutral → Buy |
2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
2020-05-19 | Eingeleitet | Citigroup | Neutral |
2020-05-19 | Eingeleitet | Guggenheim | Buy |
2020-05-19 | Eingeleitet | JP Morgan | Overweight |
2020-05-19 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Oncology Pioneer ORIC Sets Stage for 2 Major Healthcare Conference Appearances - Stock Titan
Analysts Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.86 - Defense World
Swiss National Bank Has $504,000 Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.86 - MarketBeat
Charles Schwab Investment Management Inc. Purchases 7,726 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC stock touches 52-week low at $6.31 amid market challenges By Investing.com - Investing.com South Africa
ORIC stock touches 52-week low at $6.31 amid market challenges - Investing.com Australia
PNC Financial Services Group Inc. Buys 2,520 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
ORIC® Pharmaceuticals Announces ORIC-944 Preclinical - GlobeNewswire
Breakthrough: Novel Prostate Cancer Drug Demonstrates Powerful Two-Pronged Attack Strategy - Stock Titan
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9%Time to Sell? - MarketBeat
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - Yahoo Finance
Wedbush Reaffirms Outperform Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9% – Here’s What Happened - Defense World
(ORIC) Investment Report - news.stocktradersdaily.com
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Victory Capital Management Inc. - Defense World
Oric Pharmaceuticals Expands Equity Incentive Plan for Growth - TipRanks
(ORIC) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC's Latest Employee Stock Grants: Key Details on Compensation Package - StockTitan
Rhumbline Advisers Purchases 4,072 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
ORIC Pharmaceuticals (ORIC) Projected to Post Earnings on Monday - MarketBeat
ORIC Pharmaceuticals Reports Progress in Cancer Trials - TipRanks
Wedbush Expects Increased Earnings for ORIC Pharmaceuticals - MarketBeat
ORIC Pharmaceuticals (ORIC) to Release Quarterly Earnings on Monday - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% After Analyst Upgrade - MarketBeat
(ORIC) Investment Analysis and Advice - news.stocktradersdaily.com
ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $22.00 - Defense World
ORIC Pharmaceuticals’ (ORIC) Buy Rating Reiterated at Guggenheim - Defense World
Wedbush Equities Analysts Lift Earnings Estimates for ORIC - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% on Analyst Upgrade - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $22.00 at JPMorgan Chase & Co. - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Receives "Buy" Rating from Guggenheim - MarketBeat
Oric Pharmaceuticals announces clinical development plans for ORIC-944, ORIC-114 - TipRanks
ORIC® Pharmaceuticals Announces Focused Registrational - GlobeNewswire
Can ORIC Pharmaceuticals' Extended Cash Runway Fuel Success in Cancer Drug Development? - StockTitan
Wedbush Reduces Earnings Estimates for ORIC Pharmaceuticals - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up Following Earnings Beat - MarketBeat
Finanzdaten der Oric Pharmaceuticals Inc-Aktie (ORIC)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):